Variant
ERBB2 SERUM LEVELS
CI-VAR-00004153Explore in graph →CIViC 416
Curated evidence
Evidence by cancer (2 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26811533
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Malignant Breast Neoplasm2 | ||||||||
| ERBB2 SERUM LEVELS | (prognostic) | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID973Serum and tissue levels of HER2 (ERBB2) were analyzed in 1,902 breast cancer patients treated with lapatinib or control. In the control group (n = 936), higher serum HER2 (sHER2) was associated with w… (full text at CIViC) PMID 26811533 · Lee et al., 2016 · Open in CIViC | civic |
| ERBB2 SERUM LEVELS | Lapatinib | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID972Serum and tissue levels of HER2 (ERBB2) were analyzed in 1,902 breast cancer patients treated with lapatinib or control. Serum HER2 (sHER2) levels measured by ELISA were higher in patients with HER2 a… (full text at CIViC) PMID 26811533 · Lee et al., 2016 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available